Provides an AI-driven ECG analysis tool that non-invasively maps atrial fibrillation and six other arrhythmias, delivering detailed four-chamber cardiac insights. This technology improves cardiac ablation outcomes and procedural efficiency by integrating seamlessly into existing workflows, addressing the high mortality and morbidity associated with untreated arrhythmias. FDA-cleared for seven arrhythmias and two pacing types, it transforms standard ECGs into actionable clinical data.
Funding
$36.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cardiac arrhythmias, including atrial fibrillation, pose a significant global health challenge, contributing to 10% of global deaths and increasing the risk of serious comorbidities like stroke and dementia in adults over 40. Current methods for analyzing and mapping these arrhythmias often lack the precision needed to optimize ablation outcomes and procedural efficiency.
Solution
Vektor Medical's vMap technology offers an AI-driven solution for non-invasive arrhythmia analysis and mapping, designed to improve cardiac ablation outcomes and procedural efficiency. vMap leverages standard 12-lead ECG data to provide detailed, four-chamber cardiac insights, enabling electrophysiologists to localize arrhythmias faster and target ablations with greater accuracy. The technology utilizes a comprehensive arrhythmia simulation library with over 1 million cardiac disease phenotypes, employing computational simulations and proprietary algorithms to link ECG morphology to arrhythmia localization. vMap integrates seamlessly into existing workflows, delivering rapid analysis in under 3 minutes to enhance planning and procedures.
Target Audience
The primary target audience includes electrophysiologists and other medical professionals involved in cardiac ablation procedures, as well as hospitals and cardiac centers focused on improving arrhythmia treatment outcomes.
Features
- AI-based analysis of standard 12-lead ECG data for non-invasive arrhythmia mapping
- FDA-cleared for use in mapping seven arrhythmias and two pacing types
- Provides detailed four-chamber cardiac insights
- Utilizes a comprehensive arrhythmia simulation library with over 1 million cardiac disease phenotypes
- Employs computational simulations and proprietary algorithms for ECG morphology-linked arrhythmia localization
- Delivers rapid analysis in under 3 minutes
- A prospective, multi-center RCT comparing outcomes of PVI alone vs. PVI plus vMap-guided driver ablation is underway